Titel: Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Treated With Immune Checkpoint Inhibitors Compared to Other Antineoplastic Medications: A Nationwide Study
Pharmacoepidemiology and Drug Safety · 2025-11 · 34 (11)
DOI: 10.1002/pds.70272 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 17.11.2025. Verfasst von Ida M Heerfordt und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Stevens-Johnson Syndrome, Immune Checkpoint Inhibitors, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Kongelig Hofbuntmager Aage Bangs Fond.
Abstract (Originalsprache)
Purpose
This study aimed to assess the risk of Stevens–Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) among patients treated with immune checkpoint inhibitors (ICIs), compared to those receiving molecularly targeted therapies or conventional chemotherapy, using real‐world data.
Methods
We conducted a nationwide study involving all patients treated with antineoplastic agents in Denmark from May 2018 to December 2024, identified through the Danish National Hospital Medication Registry. SJS/TEN cases were identified within 3 months of each administration using the International Classification of Diseases, 10th Revision codes L51.1 and L51.2, as recorded in the Danish National Patient Register. Incidence rates of SJS/TEN were calculated per 10 000 patients treated, and incidence rate ratios (IRRs) were estimated to compare treatment modalities.
Results
Among 91 424 patients treated with antineoplastic agents, 19 developed SJS/TEN. The incidence rates per 10 000 patients treated were 6.89 for ICIs, 1.79 for molecularly targeted therapies, and 1.51 for conventional chemotherapy. Patients receiving ICIs had a higher risk of developing SJS/TEN compared with those receiving molecularly targeted therapies (IRR 3.84, 95% CI 1.39–10.60, p = 0.009) or conventional chemotherapy (IRR 4.57, 95% CI 1.52–11.57, p = 0.001).
Conclusion
While the risk of SJS/TEN is higher among patients treated with ICIs compared to those receiving other types of antineoplastic agents, the overall incidence in the real‐world setting remains low.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.
- Department of Geriatric and Palliative Medicine, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
- Department of Respiratory Medicine and Infectious Diseases, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Ida M Heerfordt
Förderung
- Kongelig Hofbuntmager Aage Bangs Fond
Zitieren
APA
Heerfordt, I. M., Middelboe, M., Heerfordt, C. K., Horwitz, H., & Olsen, R. H. (2025). Titel: Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Treated With Immune Checkpoint Inhibitors Compared to Other Antineoplastic Medications: A Nationwide Study. Pharmacoepidemiology and Drug Safety, 34(11). https://doi.org/10.1002/pds.70272
Vancouver
Heerfordt IM, Middelboe M, Heerfordt CK, Horwitz H, Olsen RH. Titel: Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Treated With Immune Checkpoint Inhibitors Compared to Other Antineoplastic Medications: A Nationwide Study. Pharmacoepidemiology and Drug Safety. 2025;34(11). doi:10.1002/pds.70272
BibTeX
@article{Heerfordt2025,
author = {Heerfordt, Ida M and Middelboe, Magnus and Heerfordt, Christian Kjer and Horwitz, Henrik and Olsen, Rasmus Huan},
title = {Titel: Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Treated With Immune Checkpoint Inhibitors Compared to Other Antineoplastic Medications: A Nationwide Study},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2025},
volume = {34},
number = {11},
doi = {10.1002/pds.70272}
}
EUVIMED